Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)
Status:
Completed
Trial end date:
2009-03-09
Target enrollment:
Participant gender:
Summary
This is a Phase 2 multicenter, randomized, double-blind trial of MK-8777 (Org 26576, SCH
900777) in adult subjects with Attention-Deficit/Hyperactivity Disorder (ADHD). MK-8777 or
placebo will be administered in a crossover fashion for two 3-week treatment periods. The two
3-week treatment periods will be separated by a 2-week placebo washout period.
The primary objective is to compare the efficacy of various doses of MK-8777 to that of
placebo in the treatment of ADHD symptoms in adults.